Toes and colleagues
34 created the murine Ad5E1 tumor cell line by transforming embryonic C57BL/6 mouse cells with the human
Ad5E1 gene. Studies on the original Ad5E1 tumor cell line demonstrated that these tumors undergo spontaneous T-cell-dependent immune rejection in the eyes of syngeneic C57BL/6 mice.
35–37 Rejection of these original intraocular Ad5E1 tumors does not require TNF-α, FasL, TRAIL, perforin, B cells, NK cells, or CD8
+ T cells.
31,36–38 Immune rejection of Ad5E1 tumors leaves the eye anatomically intact without inflicting injury to normal ocular tissues.
37 However, during the course of our studies, we discovered that Ad5E1 tumors occasionally undergo a necrotizing form of immune rejection that leads to extensive damage to innocent bystander cells and culminates in phthisis of the tumor-containing eye.
32 Our lab isolated a clone from a subpopulation of the original Ad5E1 tumor cell line that demonstrated a high incidence of necrotizing immune rejection and phthisis of the eyes of C57BL/6 mice, designating this cell line Ad5E1 clone 2.1,
32 and that require both CD4
+ and CD8
+ T cells for intraocular tumor rejection. The clone 2.1 tumor model was used to evaluate the mechanisms that tilt the intraocular immune response from a nonnecrotizing form of immune rejection occurring in the parental Ad5E1 cell line to a necrotizing pattern of tumor rejection that occurs with clone 2.1 tumors, ridding the eye of the tumor yet culminating in destruction of the eye.
Tumor growth, AC injections, and subcutaneous (SC) injections were performed as previously described.
30